Opinion|Videos|January 13, 2025
Expanding Bispecific Therapies to Community Settings: Challenges and Innovations
Author(s)Amrita Krishnan, MD
Amrita Krishnan, MD, discusses how an ASH 2024 abstract from Sylvester Comprehensive Cancer Center suggests the potential of tocilizumab prophylaxis to mitigate cytokine release syndrome (CRS) in patients treated with bispecific therapies for multiple myeloma, and shares her approach to managing unique toxicities such as nail changes, skin reactions, and oral complications in patients receiving talquetamab.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- An ASH abstract from the group at Sylvester Comprehensive Cancer Center highlighted the potential of using tocilizumab prophylactically to mitigate CRS in patients treated with bispecific therapies for multiple myeloma. What are your thoughts on this approach, and how might it change current CRS prevention protocols?
- Talquetamab has unique toxicities such as nail changes, skin reactions, and oral complications. What are your recommendations for effectively managing these adverse events?
Advertisement
Related to this article
Experts at CHEST 2026 urge pulmonologists to keep lung cancer in mind for younger patients who never smoked, to order screening and biomarker testing themselves, and to advocate for patients' access to care.
FDA granted accelerated approval to dostarlimab-gxly for dMMR or MSI-H locally advanced rectal cancer based on interim phase 2 AZUR-1 results.
Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.
Nearly 3 in 4 bariatric surgery candidates had clinical obesity, a phenotype that BMI alone did not distinguish from preclinical obesity.
Satralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.
A review of 47 endometriosis guidelines found most came from high-income settings and diverged on biomarkers, repeat surgery, and fertility referral.
The meeting covered several topics in eye care, including how artificial intelligence (AI) can play a part in eye care.
A meta-analysis of 27 trials found a 15% cardiovascular risk reduction per 10-mm Hg lower systolic BP, with no added risk of kidney failure.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Ryzumvi for Presbyopia, Expanding its Label
2
New CHEST Guidelines Offer a Road Map for Bronchiectasis
3
FDA Grants Accelerated Approval to Dostarlimab for dMMR Rectal Cancer
4
CHEST Highlights Practice-Changing COPD Therapy and Strategies
5